Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Esperion Therapeutics Inc shares valued at $177,200 were purchased by Koenig Sheldon L. on Dec 17 ’25. At $3.67 per share, Koenig Sheldon L. acquired 48,244 shares.
Also, Looker Benjamin purchased 6,517 shares, netting a total of over 23,897 in proceeds.
Before that, Halladay Benjamin had added 7,337 shares to its account. In a trade valued at $26,906, the Officer bought Esperion Therapeutics Inc shares for $3.67 each.
As published in their initiating research note from Piper Sandler on November 25, 2025, Esperion Therapeutics Inc [ESPR] has been an Overweight and the price target has been revised to $9. Analysts at Goldman started covering the stock with ‘”a Neutral”‘ outlook in a report released in mid December. As of December 17, 2024, Cantor Fitzgerald has initiated its “an Overweight” rating for ESPR. Earlier on June 20, 2024, BofA Securities downgraded its rating. Their new recommendation was “an Underperform” for ESPR stock which previously was a “a Neutral”.
Analyzing ESPR Stock Performance
On last trading session, Esperion Therapeutics Inc [NASDAQ: ESPR] plunged -1.62% to $3.65. The stock’s lowest price that day was $3.63, but it reached a high of $3.75 in the same session. During the last five days, there has been a drop of approximately -4.70%. Over the course of the year, Esperion Therapeutics Inc shares have jumped approximately 62.22%. Shares of the company reached a 52-week high of $4.13 on 12/12/25 and a 52-week low of $0.69 on 05/15/25.
Support And Resistance Levels for Esperion Therapeutics Inc (ESPR)
According to the 24-hour chart, there is a support level at 3.60, which, if violated, would cause prices to drop to 3.56. In the upper region, resistance lies at 3.72. The next price resistance is at 3.80. RSI (Relative Strength Index) is 54.01 on the 14-day chart, showing neutral technical sentiment.
Is Esperion Therapeutics Inc subject to short interest?
Stocks of Esperion Therapeutics Inc saw a sharp rise in short interest on 2025-11-28 jumping by 2.81 million shares to 28.73 million. Data from Yahoo Finance shows that the short interest on 2025-10-31 was 25.92 million shares. A jump of 9.77% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 4.0 of the overall float, the days-to-cover ratio (short ratio) jumped to 4.0.
Which companies own the most shares of Esperion Therapeutics Inc (ESPR)?
In terms of Esperion Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 9 in the next 12 months, up nearly 142.59% from the previous closing price of $3.71. Analysts anticipate Esperion Therapeutics Inc stock to reach 9 by 2025, with the lowest price target being 9. In spite of this, 8 analysts ranked Esperion Therapeutics Inc stock as Buy at the end of 2025.
